ENT Intersection (NASDAQ:XENT – Get Note) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report released Friday to clients and investors.
XENT stock traded down $0.17 during Friday’s session, hitting $27.33. The stock recorded trading volume of 93,124 shares, compared to an average trading volume of 222,451 shares. The company’s 50-day moving average is $27.26 and its two-hundred-day moving average is $27.23. The company has a market capitalization of $914.52 million, a price-earnings ratio of -10.20 and a beta of 1.56. Intersect ENT has a one-year low of $15.92 and a one-year high of $28.17. The company has a quick ratio of 1.97, a current ratio of 2.36 and a debt ratio of 6.89.
Institutional investors have recently changed their stake in the company. Alpine Associates Management Inc. acquired a new stake in Intersect ENT during the 3rd quarter at a value of $37,889,000. CNH Partners LLC acquired a new stake in Intersect ENT in the third quarter valued at approximately $9,846,000. Capstone Investment Advisors LLC purchased a new stake in shares of Intersect ENT during the third quarter for a value of approximately $3,439,000. Grandeur Peak Global Advisors LLC increased its holdings in Intersect ENT by 154.7% in the second quarter. Grandeur Peak Global Advisors LLC now owns 75,398 shares of the medical equipment supplier valued at $1,289,000 after buying an additional 45,800 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Intersect ENT shares by 35.2% during the third quarter. Russell Investments Group Ltd. now owns 44,972 shares of the medical equipment supplier valued at $1,223,000 after acquiring 11,718 additional shares in the last quarter. Institutional investors hold 92.85% of the company’s shares.
Company profile Intersect ORL (Get an evaluation)
Intersect ENT, Inc. is a commercial drug delivery company, dedicated to the treatment of ear, nose and throat conditions. Its products include PROPEL and SINUVA. PROPEL is used to maintain openness and locally deliver steroids after sinus surgery. The SINUVA is used to treat adult patients who have had ethmoid sinus surgery but have recurrent sinus obstruction due to polyps.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Intersect ENT right now?
Before you consider Intersect ENT, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and Intersect ENT was not on the list.
While Intersect ENT currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here